- Home
- IMAX vs XERS Comparison
IMAX vs XERS Comparison
Compare IMAX & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAX
- XERS
- Stock Information
- Founded
- IMAX 1967
- XERS 2005
- Country
- IMAX Canada
- XERS United States
- Employees
- IMAX N/A
- XERS N/A
- Industry
- IMAX
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- IMAX
- XERS Health Care
- Exchange
- IMAX Nasdaq
- XERS Nasdaq
- Market Cap
- IMAX 1.3B
- XERS 1.3B
- IPO Year
- IMAX 1994
- XERS 2018
- Fundamental
- Price
- IMAX $32.36
- XERS $7.49
- Analyst Decision
- IMAX Strong Buy
- XERS Strong Buy
- Analyst Count
- IMAX 9
- XERS 7
- Target Price
- IMAX $32.44
- XERS $8.00
- AVG Volume (30 Days)
- IMAX 1.1M
- XERS 2.0M
- Earning Date
- IMAX 10-29-2025
- XERS 11-07-2025
- Dividend Yield
- IMAX N/A
- XERS N/A
- EPS Growth
- IMAX 52.36
- XERS N/A
- EPS
- IMAX 0.60
- XERS N/A
- Revenue
- IMAX $362,475,000.00
- XERS $246,025,000.00
- Revenue This Year
- IMAX $16.96
- XERS $43.89
- Revenue Next Year
- IMAX $5.72
- XERS $20.40
- P/E Ratio
- IMAX $54.17
- XERS N/A
- Revenue Growth
- IMAX 1.25
- XERS 35.62
- 52 Week Low
- IMAX $18.76
- XERS $2.69
- 52 Week High
- IMAX $32.36
- XERS $8.03
- Technical
- Relative Strength Index (RSI)
- IMAX 80.08
- XERS 55.56
- Support Level
- IMAX $28.42
- XERS $7.56
- Resistance Level
- IMAX $31.37
- XERS $7.89
- Average True Range (ATR)
- IMAX 0.86
- XERS 0.24
- MACD
- IMAX 0.41
- XERS -0.12
- Stochastic Oscillator
- IMAX 99.91
- XERS 13.60
About IMAX Imax Corporation
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).